Table 1.
Baseline patient characteristics and concomitant treatments
| Monotherapy (n = 167) | Primary biotherapy (n = 88) | Secondary biotherapy (n = 57) | Total (n = 312) | |
|---|---|---|---|---|
| Sex | ||||
| Male | 79 (47.3%) | 51 (58.0%) | 35 (61.4%) | 165 (52.9%) |
| Female | 88 (52.7%) | 37 (42.0%) | 22 (38.6%) | 147 (47.1%) |
| Age at diagnosis (year)a | 40.0 ± 13.5 | 39.2 ± 14.4 | 38.5 ± 12.4 | 39.5 ± 13.5 |
| Age at PEG start (year)a | 47.7 ± 13.4 | 45.1 ± 16.1 | 43.4 ± 13.5 | 46.2 ± 14.3 |
| Age at inclusion in ACROSTUDY (year)a | 49.4 ± 13.4 | 47.0 ± 16.0 | 45.2 ± 14.0 | 48.0 ± 14.4 |
| Time between diagnosis and PEG start (year)a | 7.8 ± 7.8 | 5.9 ± 6.0 | 4.9 ± 5.8 | 6.7 ± 7.1 |
| Prior surgery | ||||
| No, n (%) | 40 (24.0%) | 25 (28.4%) | 9 (15.8%) | 74 (23.7%) |
| Yes, n (%) | 127 (76.0%) | 63 (71.6%) | 48 (84.2%) | 238 (76.3%) |
| Prior radiotherapy | ||||
| No, n (%) | 119 (71.3%) | 66 (75.0%) | 44 (77.2%) | 229 (73.4%) |
| Yes, n (%) | 48 (28.7%) | 22 (25.0%) | 13 (22.8%) | 83 (26.6%) |
| Prior SA | ||||
| No, n (%) | 13 (7.8%) | 3 (3.4%) | 3 (5.3%) | 19 (6.1%) |
| Yes, n (%) | 154 (92.2%) | 85 (96.6%) | 54 (94.7%) | 293 (93.9%) |
| Prior DA | ||||
| No, n (%) | 100 (59.9%) | 49 (55.7%) | 37 (64.9%) | 186 (59.6%) |
| Yes, n (%) | 67 (40.1%) | 39 (44.3%) | 20 (35.1%) | 126 (40.4%) |
| Concomitant SA | ||||
| No, n (%) | 167 (100.0%) | 0 (0.0%) | 0 (0.0%) | 167 (53.5%) |
| Yes, n (%) | 0 (0.0%) | 88 (100.0%) | 57 (100.0%) | 145 (46.5%) |
| Concomitant DA | ||||
| No, n (%) | 136 (81.4%) | 62 (70.5%) | 39 (68.4%) | 237 (76.0%) |
| Yes, n (%) | 31 (18.6%) | 26 (29.5%) | 18 (31.6%) | 75 (24.0%) |
PEG pegvisomant, GH growth hormone, DA dopamine agonist, SA somatostatin analog
aMean ± SD